Company Overview - Zhenbaodao (SH 603567) announced that as of the disclosure date, the total amount of external guarantees provided by the company is RMB 1.755 billion, accounting for 22.5% of the latest audited net assets [1] - The total guarantees for wholly-owned subsidiaries amount to RMB 1.555 billion, representing 19.93% of the latest audited net assets [1] - The guarantees for associated companies total RMB 200 million, which is 2.56% of the latest audited net assets [1] Revenue Composition - For the year 2024, the revenue composition of Zhenbaodao is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical commerce accounts for 11.13%, and other businesses account for 1.09% [1] Market Capitalization - As of the report, Zhenbaodao has a market capitalization of RMB 9.6 billion [1]

关于新增为全资子公司提供担保额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 亳州中药材商品交易中心有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 40,000.00 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 33,500.00 | 万元 | | | | 是否在前期预计额度内 | □是 | ☑否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 175,500 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 22.50 | | 特别风险提示 | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 50% ...

2 2025.12.11 1 目录 | 2025 | 年第三次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第三次临时股东会会议议程 4 | | 议案 | 1：关于续聘公司 2025 年度审计机构的议案 6 | 黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会 会 议 资 料 黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率， 根据《公司法》《上市公司股东会规则》《上海证券交易所上市公司 自律监管指引第1号——规范运作》及《公司章程》等相关规定，特 制定本次股东会须知如下： 一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东会，依法享有发言权、质询权、表决权等权利， 并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在2025年12月9日上午9时—11时，下 午14时—16时到黑龙江珍宝岛药业股份有限公司（以下简称"公司"） 或者通过电子邮件等形式办理参会登记。已办理参会登记的股东及股 东代表需携带身份证明、授权委 ...

Core Viewpoint - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has received a drug registration certificate for Moxifloxacin Hydrochloride Tablets, indicating an expansion in its product portfolio and enhancing its competitive position in the anti-infection market [1][4]. Drug Basic Information - The drug is Moxifloxacin Hydrochloride Tablets, with a specification of 0.4g and classified as a prescription drug [1]. - The drug registration certificate number is 2025S03558, and it is valid for 36 months, expiring on November 24, 2030 [1]. - The drug is approved for various infections, including acute bacterial sinusitis and community-acquired pneumonia [2]. Market and Financial Impact - Moxifloxacin Hydrochloride Tablets have been included in the National Basic Medical Insurance Directory for 2024, with a projected market size of 530 million RMB in China [3]. - The company has invested 13.64 million RMB in the research and development of this drug [3]. - There are currently 24 approved manufacturers for Moxifloxacin Hydrochloride Tablets in China [3]. Company Impact - The approval of Moxifloxacin Hydrochloride Tablets enhances the company's core product offerings in the anti-infection sector, thereby improving its market competitiveness [4]. - The company aims to broaden its business scope and strengthen its product matrix with this new addition [4].

Core Viewpoint - The company, Zhenbao Island (603567.SH), announced that its wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its pharmaceutical offerings [1] Group 1 - The approved drug is indicated for the treatment of various conditions including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of infections [1] - The drug is specifically approved for use in adults aged 18 and older, expanding the company's product portfolio in the pharmaceutical market [1] - The conditions treated by the drug include non-complicated and complicated skin and soft tissue infections, complicated intra-abdominal infections, plague, and mild to moderate pelvic inflammatory disease without associated tubo-ovarian or pelvic abscess [1]

Core Viewpoint - The company, Zhenbao Island (603567), has received approval from the National Medical Products Administration for its subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. to market Moxifloxacin Hydrochloride Tablets, indicating a significant advancement in its pharmaceutical offerings [1]. Group 1: Product Approval - The approved drug, Moxifloxacin Hydrochloride Tablets, is indicated for the treatment of various infections, including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of skin and intra-abdominal infections [1]. - The approval highlights the company's commitment to expanding its product portfolio in the pharmaceutical sector, particularly in addressing serious bacterial infections [1].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-081 黑龙江珍宝岛药业股份有限公司 1 莫西沙星是具有广谱活性和杀菌作用的 8-甲氧基氟喹诺酮类抗菌药。莫西 沙星在体外显示出对革兰阳性菌、革兰阴性菌、厌氧菌、抗酸菌和非典型微生物 如支原体、衣原体和军团菌具有广谱抗菌活性。其杀菌作用机制为干扰拓扑异构 酶Ⅱ和Ⅳ。拓扑异构酶是控制 DNA 拓扑和在 DNA 复制、修复和转录中关键的酶。 莫西沙星表现为浓度依赖性的杀菌活性。最低杀菌浓度和最低抑菌浓度基本一致。 莫西沙星对β-内酰胺类和大环内酯类耐药的细菌亦有效。通过感染的实验动物 模型证实，莫西沙星体内活性高。 盐酸莫西沙星片（商品名：Avelox ®）由 Bayer Vital GmbH 研发并于 1999 年在德国首次上市，2002 年盐酸莫西沙星片（商品名：拜复乐）在中国上市。 用于治疗成人（≥18 岁）急性细菌性鼻窦炎、慢性支气管炎急性发作、社区获 得性肺炎、非复杂性皮肤和皮肤组织感染、复杂性皮肤和皮肤组织感染、复杂性 腹腔内感染、鼠疫、不伴有输卵管-卵巢或盆腔脓肿的轻至中度盆腔炎性疾病。 关于全资子公司获得药品注册证书的公告 本公司董 ...

Core Viewpoint - The company has received approval for the production and sale of Moxifloxacin Hydrochloride Tablets, enhancing its product portfolio in the anti-infection sector [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration [1]. - Moxifloxacin is a broad-spectrum antibacterial agent effective against various bacteria, including Gram-positive, Gram-negative, anaerobic, and atypical microorganisms [1]. Group 2: Market Impact - The approval allows the company to expand its core product offerings in the anti-infection field, thereby increasing its competitiveness in the systemic anti-infection market [2]. - The introduction of Moxifloxacin Hydrochloride Tablets will not have a significant impact on the company's current operating performance [2].

Core Viewpoint - The announcement by Zhenbao Island (603567) regarding the approval of moxifloxacin hydrochloride tablets by the National Medical Products Administration indicates a significant development in the company's pharmaceutical portfolio, potentially enhancing its market position in the antibacterial drug segment [1] Group 1: Company Developments - Zhenbao Island's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for moxifloxacin hydrochloride tablets [1] - The company has invested approximately 13.64 million RMB in the research and development of this drug [1] Group 2: Market Context - Moxifloxacin hydrochloride is a broad-spectrum antibacterial agent used for treating various bacterial infections [1] - There are currently 24 approved manufacturers of moxifloxacin hydrochloride tablets in China, with a market size reaching 530 million RMB [1] - The production and sales of this drug are subject to significant uncertainties due to national policies and market environment changes [1]

Core Viewpoint - The announcement from the Heilongjiang Provincial Drug Administration confirms that the inspections conducted on Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. and Harbin Fangsheng Pharmaceutical Technology Co., Ltd. have met the GAP (Good Agricultural Practices) requirements for traditional Chinese medicine materials [3]. Group 1: Inspection Results - The inspections were carried out from November 7 to November 9, 2025, and the results indicated compliance with GAP standards [3]. - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has a cultivation area of 2,920 acres, with an expected yield of 150,020 kg for its Astragalus injection products [3]. - Harbin Fangsheng Pharmaceutical Technology Co., Ltd. has a cultivation area of 3,120 acres, with an expected yield of 159,380 kg for its Astragalus injection products [3]. Group 2: Product Specifications - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. produces Astragalus injections in two specifications: 10ml (National Drug Approval Number Z23020782) and 20ml (National Drug Approval Number Z23020862) [3]. - Harbin Fangsheng Pharmaceutical Technology Co., Ltd. produces Astragalus injections in a 2ml specification (National Drug Approval Number Z23020781) [3]. Group 3: Geographic Information - The geographic coordinates for Heilongjiang Zhenbaodao's cultivation base include multiple points: - Point 1: East Longitude 104°31′457″, North Latitude 34°40′529″ - Point 2: East Longitude 104°32′719″, North Latitude 34°41′333″ - Point 3: East Longitude 104°32′839″, North Latitude 34°39′273″ - Point 4: East Longitude 104°31′784″, North Latitude 34°38′567″ [3]. - The geographic coordinates for Harbin Fangsheng's cultivation base also include multiple points: - Point 1: East Longitude 104°34′194″, North Latitude 34°41′713″ - Point 2: East Longitude 104°32′735″, North Latitude 34°41′218″ - Point 3: East Longitude 104°35′038″, North Latitude 34°41′439″ - Point 4: East Longitude 104°33′261″, North Latitude 34°39′796″ [4].